About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

USFDA Lifts Clinical Hold On Three Cancer Drugs of Advaxis

by Reshma Anand on December 17, 2015 at 3:37 PM
Font : A-A+

USFDA Lifts Clinical Hold On Three Cancer Drugs of Advaxis

Advaxis has announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on IND applications of its three drugs. Advaxis is a biotechnology company focused on developing cancer immunotherapies.

The company is currently developing three products namely axalimogene filolisbac, ADXS-PSA and ADXS-HER2. In October 2015, Advaxis received a notification from the FDA that its IND applications for axalimogene filolisbac were put on clinical hold in response to the company's submission of a safety report to the FDA.

Advertisement


After discussions with FDA, the company has agreed to implement certain risk mitigation measures like post-administration antibiotic treatment, patient surveillance and monitoring measures.

"We appreciate the FDA's review of this matter. We are grateful that our clinical trials will now resume so that we may continue investigating new treatments for unmet medical needs. We thank both the patients and their physicians for their participation in our clinical trials," said Daniel J. O'Connor, President and Chief Executive Officer of Advaxis.
Advertisement

Now, Advaxis will resume all clinical trials with axalimogene filolisbac, ADXS-PSA and ADXS-HER2. Axalimogene filolisbac is a treatment for HPV-associated cancers and is in clinical trials for three potential indications: invasive cervical cancer, head and neck cancer and anal cancer.

ADXS-PSA is in clinical development for targeting the prostate-specific antigen (PSA) associated with prostate cancer. Advaxis is developing ADXS-HER2 for the treatment of osteosarcoma in both animals and humans.

Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Know More About Mitochondria
Top 10 Foods for Decreasing DHT Production and Preventing Hair Fall
Alarming Cesarean Section Trends in India - Convenience or Compulsion of Corporate Healthcare
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Cancer and Homeopathy Cancer Facts Cancer Tattoos A Body Art Drugs Banned in India Common Lifestyle Habits that Cause Diseases Health Benefits of Dandelion Plant Immune Checkpoint Inhibitors for Cancer Treatment Non-Communicable Diseases 

Most Popular on Medindia

Sanatogen Blood Pressure Calculator Accident and Trauma Care Find a Doctor Color Blindness Calculator How to Reduce School Bag Weight - Simple Tips Find a Hospital Selfie Addiction Calculator Indian Medical Journals Nutam (400mg) (Piracetam)
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

USFDA Lifts Clinical Hold On Three Cancer Drugs of Advaxis Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests